Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
47 authors.
Chin-Ann Johnny Ong *Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0003-4573-7738
Joseph J Zhao *Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-2002-5390
Ying Liu *Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-4726-7816
Supriya SrivastavaDepartment of Medicine, National University Hospital, Singapore, Singapore.ORCID 0000-0002-6727-3076
Daryl K A ChiaDepartment of Surgery, National University Hospital, National University Health System, Singapore, Singapore.ORCID 0000-0001-9936-1225
Ying En QuekYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0009-0000-8416-8924
Xiaonan FanCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-3308-2201
Haoran MaCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0004-9614-1832
Kie Kyon HuangCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4104-8951
Taotao ShengGenome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore.ORCID 0000-0003-3809-4885
Qiu Xuan TanDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-5700-1739
Gillian NgDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0003-1722-8506
Joey W S TanDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0001-6620-6085
Jia-Ying Joey LeeBioinformatics Institute (BII), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.ORCID 0000-0002-0420-7098
Lit-Hsin LooBioinformatics Institute (BII), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.ORCID 0000-0001-6303-9840
Li Yen ChongInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID 0000-0002-4623-4633
Xue Wen OngCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0000-4518-5166
Su Ting TayCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-3609-0143
Takeshi HagiharaCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0007-9263-1553
Angie TanCancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-8238-0515
Craig Ryan Cecil JosephInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID 0009-0004-5326-9692
Melissa C C TeoDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0007-8148-6012
Josephine HendriksonDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-2051-4063
Clara Y L ChongDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0001-6796-9914
Wanyu GuoDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0002-4035-0710
Claramae S ChiaDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0007-5770-9757
Jolene S M WongDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-9750-5755
Chin Jin SeoDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0009-0005-3582-4258
Mingzhe CaiDepartment of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.ORCID 0000-0002-0561-7312
Yvonne TayCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-4989-9101
Kevin M S SimDepartment of Pathology, National University Hospital, Singapore, Singapore.ORCID 0009-0003-1472-8502
Ryan Y K TayYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-9773-411X
Robert WalshDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.ORCID 0000-0003-0985-606X
Marcello GuaglioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-8194-9810
Federica MoranoMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-5306-3596
Ming TehDepartment of Medicine, National University Hospital, Singapore, Singapore.ORCID 0000-0001-6879-8678
Huey Yew Jeffrey LumDepartment of Pathology, National University Hospital, Singapore, Singapore.ORCID 0000-0002-3513-2404
Tony K H LimDepartment of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0003-0645-5164
Louis VermeulenAmsterdam UMC Location University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Amsterdam, the Netherlands.ORCID 0000-0002-6066-789X
Maarten F BijlsmaAmsterdam UMC Location University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Amsterdam, the Netherlands.ORCID 0000-0001-6627-3229
Kristiaan LenosAmsterdam UMC Location University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Amsterdam, the Netherlands.ORCID 0000-0003-1165-8732
Samuel J KlempnerDivision of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-4062-0808
Joe P S YeongInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID 0000-0002-6674-7153
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
Agency for Science, Technology and Research (A*STAR) A*STAR Biomedical Engineering Programme (C211318003)Agency for Science, Technology and Research (A*STAR) A*STAR I&E GAP Fund (I24D1AG082)Agency for Science, Technology and Research (A*STAR) Industry Alignment Fund-Industry Collaboration Fund (IAF-ICP I2201E0014)National Medical Research Council (NMRC) MOH-000323-00National Medical Research Council (NMRC) MOH-000967National Medical Research Council (NMRC) MOH-CIRG21jun-0005National Medical Research Council (NMRC) MOH-CIRG24jan-0044National Medical Research Council (NMRC) MOH-CSAINV22jul-0005National Medical Research Council (NMRC) MOH-OFLCG18May-0003National Medical Research Council (NMRC) MOH-OFLCG23-may0031National Medical Research Council (NMRC) MOH-OFYIRG24jan-0052National Medical Research Council (NMRC) NMRC/CIRG23Jul-0035National Medical Research Council (NMRC) NMRC/MOH-000627National Medical Research Council (NMRC) OFYIRG19may-0007National University Health System (NUHS) JRA/Sep23/002National University Health System (NUHS) NUHSRO/2024/008/RO5+6/Seed-Sep23/01National University of Singapore (NUS) Dean's Research Development AwardNCI NIH HHS P50 CA127003
6 · The paper itself
Abstract
purposePeritoneal metastases (PM) in colorectal cancer portend a poor prognosis. We sought to elucidate molecular features differentiating primary tumors (PT) from PMs and actionable targets facilitating transcoelomic dissemination and progression. EXPERIMENTAL
designWe performed multiomic profiling of 227 samples from 136 patients, including 56 PTs and 120 synchronous PMs comprising 34 matched PT-PM pairs. Whole-exome and bulk RNA sequencing analyses were conducted to identify underlying genomic aberrations and transcriptomic differences between primary and peritoneal lesions. We spatially characterized the microenvironment of tumor-stroma compartments and studied the roles of stromal phenotypes in promulgating tumorigenesis.
resultsWhole-exome sequencing found that genomic alterations and clonality patterns between PTs and PMs remain broadly similar. Transcriptomic profiles, however, suggest a transition as tumors reach the peritoneum toward a more mesenchymal tumor profile and fibrotic tumor microenvironment. Applying spatial profiling, we identify a fibro-collagenous and immune-infiltrated stromal phenotype [stromal cluster (SC) 2] characterized by increased cancer-associated fibroblasts, memory B cells, M2 macrophages, and T-cell exhaustion. These findings were orthogonally validated by multiplex IHC. Patients with SC2 stroma had poorer survival and were characterized by high SERPINE-1 (PAI-1) expression. PMs in patients with SC2 stroma were associated with enriched oncogenic pathways such as TGF-β. PAI-1 inhibition of colorectal cancer PM cell lines with a novel biologic demonstrated reduced IL2-STAT5 and TGF-β pathways and cell death.
conclusionsOur findings unveil distinctive and actionable molecular signatures, offering deeper insights into the intricate cross-talk between tumor cells and stromal microenvironments enabling PM in colorectal cancer.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis. · full record | OpenQuestion